Navigation Links
Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
Date:1/7/2008

//studio-5.financialcontent.com/prnews?Page=Quote&Ticker=AVAN" onClick="var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >AVAN) in October 2007.

"Fast Track status acknowledges CDX-110's potential to fill an unmet need for glioblastoma patients and gives it priority within the FDA," said Thomas Davis, M.D., Chief Medical Officer of Celldex Therapeutics. "Confirmation of the promising results we've already observed is a high priority at Celldex, as it is within the brain cancer community in general."

About CDX-110

CDX-110 is an investigational immunotherapy that targets the tumor specific molecule EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), which is a protein that has been well validated as a target for cancer therapy. This particular variant, EGFRvIII occurs in about 40 percent of Glioblastoma Multiforme (GBM) patients. It was discovered in a collaborative effort between Dr. Bert Vogelstein and Dr Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Unlike EGFR, EGFRvIII is not present in normal tissues, suggesting this target will enable the development of a tumor-specific therapy for cancer patients. Furthermore, EGFRvIII is a transforming oncogene that can directly contribute to cancer cell growth. While originally discovered in GBM, the most common and aggressive form of brain cancer, the expression of EGFRvIII has also been observed in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head & neck cancers. Celldex has exclusive rights to EGFRvIII vaccines and is pursuing the development of CDX-110 for GBM therapy, as well as in other cancers through additional clinical studies.

About Fast Track Drug Designation

Under the FDA Modernization Act of 1997, designation as a Fast Track product for a new drug or biological products means that FDA will take such actio
'/>"/>

SOURCE Celldex Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, ... Boston and their first West Coast location in ... Street in Boston , and will house product ... Southern California office will be located at ... the demands of customers nationwide.  Both new locations will be ...
(Date:9/16/2014)... Sept. 16, 2014  Formex, LLC ("Formex"), ... that Mr. Greg Weilersbacher joined Formex as Director ... Greg Weilersbacher has ... focused expertise in Quality Assurance, Facility Validation, ... Weilersbacher brings to Formex a diverse wealth ...
Breaking Medicine Technology:Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... R.I., Aug. 16, 2011 Medicare Part D beneficiaries ... pay 100 percent of previously subsidized prescription costs, are ... are to switch to more affordable or generic medications, ... concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) The ...
... Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... Phase III clinical studies in patients with refractory chronic ... of the American Medical Association ( JAMA ). ... significant and sustained reductions in uric acid levels along ...
Cached Medicine Technology:CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:9/16/2014)... pain clinic as a testing ground, researchers at Johns ... by Toyota in Japan can substantially reduce patient wait ... residents. , In a report on the pilot study, ... the researchers adopted the so-called "Just-in-Time" training and inventory ... to stem waste and keep complicated operations from bottlenecking. ...
(Date:9/16/2014)... Va. (PRWEB) September 16, 2014 ... through predictive analytics and targeted clinical programs, today ... announced changes support the Company’s drive to improve ... and targeted clinical programs. On September 2, 2014, ... company, Millennium Health, announced that RxAnte founder and ...
(Date:9/16/2014)... Thompson HealthDay Reporter MONDAY, ... strong heart fitness can delay a man,s onset of age-related ... suggests. Blood pressure naturally increases as people grow older ... with strong cardio-fitness don,t start drifting toward high blood pressure ... usually experience the early signs of high blood pressure in ...
(Date:9/16/2014)... early-stage lung cancer who receive stereotactic body radiation ... 40 percent, according to research presented today at ... Annual Meeting. Such a positive survival rate is ... poor tumor control for patients with inoperable lung ... 0236, originally published in 2010 , and also ...
(Date:9/16/2014)... West Orange, NJ. September 16, 2014. Kessler Foundation ... of slowed processing speed in the executive deficits ... "Does slowed processing speed account for executive deficits ... structural neuroimaging," was published online ahead of print ... The authors are Victoria Leavitt, PhD, ...
Breaking Medicine News(10 mins):Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 2Health News:Long-term results of RTOG 0236 confirm good primary tumor control, positive 5-year survival rates 3
... ... in designing cutting-edge training facility for Kodak Dental Systems that features practice management ... ... August 4, 2009 -- Advanced Automation, a leader in comprehensive IT solutions and ...
... , ROSEMONT, Ill., Aug. 4 ... such anesthetic drugs as Diprivan (propofol) by the late Michael Jackson, ... agents. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO ... and Maxillofacial Surgeons (AAOMS) and its 8,500 fellows and members who ...
... , , , ... (Pink Sheets: NXCO), developer of next generation digital media protection ... , a website that provides authors in the self-help/motivational market ... their downloadable materials. AmnestyQuest.com is a partnership between Nexicon and ...
... MINNEAPOLIS, Aug. 4 Court ordered Class Notice in Curtis, et al., ... , court File No. 27-CV-01-18042 (action filed 11/28/01). , , ... at any time before November 30, 2004, this class action notice may affect ... the marketing, advertising and promotion of Marlboro Lights cigarettes is pending in Hennepin ...
... , AVENTURA, Fla., Aug. 4 ... of highly specialized, nationally recognized orthopedic surgeons who have agreed ... business model of Centers of Excellence with Global Convenience(TM) ... orthopedic procedures domestically and abroad. The team represents a total ...
... ... has introduced a new technology offering including their new Scoreboard application. ... at a glance screen showing key business indicators updated in real-time. ... or both. The Scoreboard will be available to clients that either ...
Cached Medicine News:Health News:New Kodak Training Facility Showcases the Latest in Dental Technology, Solutions from Advanced Automation: Networking Solutions, Dental Practice Management and Dental X-Ray Integration 2Health News:New Kodak Training Facility Showcases the Latest in Dental Technology, Solutions from Advanced Automation: Networking Solutions, Dental Practice Management and Dental X-Ray Integration 3Health News:American Association of Oral and Maxillofacial Surgeons Says Only Trained Dental and Medical Practitioners Should Administer and Monitor Anesthesia 2Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 2Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 3Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 4Health News:Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry 5Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 2Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 3Health News:Mobile Surgery International Assembles Team of Nationally Recognized Orthopedic Surgeons 2Health News:Mobile Surgery International Assembles Team of Nationally Recognized Orthopedic Surgeons 3Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 2Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: